. Author manuscript; available in PMC: 2021 Jul 1.

Published in final edited form as: Mayo Clin Proc. 2020 Jul;95(7):1342–1353. doi: 10.1016/j.mayocp.2020.03.025

Table 4:

Multivariable linear regression evaluating the association of metabolic variables and secondary neuropathy outcome measures

Variable	Sqrt(IENFD leg) Parameter estimate (m/s) (95%CI)	Sural amplitude Parameter estimate (uV) (95%CI)	Tibial F Parameter estimate (uV) (95%CI)	Log(Peroneal DML) Parameter estimate (uV) (95%CI)	Tibial amplitude Parameter estimate (mV) (95%CI)
Age	−0.05 (−0.06,−0.03)^*	−0.17 (−0.27,−0.07)^*	0.17 (0.10,0.24)^*	0.00 (0.00,0.01)^*	−0.08 (−0.16,0.00)^*
Female (reference male)	−0.29 (−0.82,0.24)	−0.98 (−4.37,2.42)	−0.78 (−3.21,1.66)	−0.02 (−0.12,0.09)	1.12 (−1.50,3.75)
Height unit=5 cm	−0.25 (−0.36,−0.14)^*	−0.69 (−1.40,0.02)	1.94 (1.43,2.46)^*	0.04 (0.02,0.06)^*	−0.40 (−0.95,0.15)
Glycemic status Pre-diabetes (reference normal)	0.05 (−0.37,0.47)	2.90 (0.25,5.55)^*	0.50 (−1.44,2.43)	0.00 (−0.08,0.09)	−0.26 (−2.35,1.83)
Diabetes (reference normal)	−0.27 (−0.73,0.19)	0.41 (−2.51,3.33)	2.09 (−0.09,4.27)	0.10 (0.01,0.19)^*	−2.17 (−4.48,0.14)
SBP unit=10 mm Hg	−0.18 (−0.29,−0.06)^*	−1.10 (−1.81,−0.39)^*	0.09 (−0.44,0.63)	−0.01 (−0.03,0.02)	−0.44 (−1.00,0.12)
Triglycerides unit=50 mg/dL	−0.14 (−0.23,−0.05)^*	0.01 (−0.58,0.60)	0.32 (−0.12,0.75)	0.01 (−0.01,0.03)	0.19 (−0.28,0.66)
HDL unit=10 mg/dL	0.11 (−0.05,0.26)	−0.09 (−1.08,0.90)	0.39 (−0.34,1.11)	0.00 (−0.03,0.03)	−0.14 (−0.91,0.64)
NCEP Waist Circumference unit=5 cm	−0.08 (−0.12,−0.03)^*	−0.39 (−0.69,−0.10)^*	0.08 (−0.14,0.30)	−0.01 (−0.02,0.00)	−0.19 (−0.42,0.04)

=p<0.05

Sqrt=square root, IENFD=intraepidermal nerve fiber density, DML=distal motor latency, SBP=systolic blood pressure, HDL=high density lipoprotein